Cynata Therapeutics Limited (ASX:CYP) Requests Trading Halt
Request for Trading Halt
Cynata Therapeutics Limited (ASX: CYP) has requested an immediate trading halt on its securities. This decision is in relation to the pending announcement of the results from the phase 1 clinical trial for diabetic foot ulcers. The trading halt is expected to last until the earlier of the announcement’s release or the commencement of normal trading on Friday, 6 December 2024.
Company Compliance Statement
In compliance with Listing Rule 17.1, Cynata confirms that it is not aware of any reasons why the trading halt should not be granted. Additionally, the company is not aware of any other information necessary to inform the market regarding the halt.
About Cynata Therapeutics
Cynata Therapeutics Limited is an Australian clinical-stage company that focuses on developing therapies using its proprietary Cymerus™ stem cell platform technology. The company is actively conducting clinical trials for several conditions, including its lead candidate, CYP-001, for the treatment of steroid-resistant acute graft-versus-host disease.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.